Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Glenmark Life Sciences LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:543322NSE Symbol: GLSP/E(TTM):21.43
ISIN Demat:INE03Q201024Div & Yield %:2.73EPS(TTM):38.43
Book Value(Rs):190.3516907Market Cap ( Cr.):10090.73Face Value(Rs):2
    Change Company 
( In Cr)
 Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
INCOME :      
Sales Turnover 2161.222123.211885.171537.31886.420.25
Excise Duty0.000.000.000.000.000.00
Net Sales2161.222123.211885.171537.31886.420.25
Other Income 28.9614.700.8111.990.440.00
Stock Adjustments 84.44-41.3270.704.64301.59-0.05
Total Income2274.622096.591956.681553.941188.450.20
EXPENDITURE :      
Raw Materials 1068.56977.96948.17668.66633.560.04
Power & Fuel Cost115.60100.9274.1976.7557.810.00
Employee Cost 180.18168.72149.13142.28106.280.15
Other Manufacturing Expenses 137.17124.04107.32108.0477.090.00
Selling and Administration Expenses 65.9948.6448.5042.0544.200.00
Miscellaneous Expenses 35.8745.5637.4932.2221.350.02
Less: Pre-operative Expenses Capitalised0.000.000.000.000.000.00
Total Expenditure1603.361465.831364.801069.99940.290.22
Operating Profit671.25630.76591.89483.96248.17-0.01
Interest 0.5527.9687.5533.520.610.00
Gross Profit670.70602.80504.34450.44247.56-0.01
Depreciation42.0937.8833.3929.3719.260.00
Profit Before Tax628.61564.92470.95421.07228.30-0.01
Tax150.61137.63112.7598.5425.900.00
Fringe Benefit tax0.000.000.000.000.000.00
Deferred Tax11.048.576.629.436.810.42
Reported Net Profit466.96418.72351.58313.10195.59-0.43
Extraordinary Items -0.41-0.55-0.44-0.91-0.540.00
Adjusted Net Profit467.37419.27352.02314.01196.13-0.43
Adjst. below Net Profit -0.29-19.50-0.530.47-108.020.00
P & L Balance brought forward1021.35750.79399.7386.17-1.41-0.97
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 385.96128.650.000.000.000.00
P & L Balance carried down1102.061021.35750.79399.7386.17-1.41
Dividend0.000.000.000.000.000.00
Preference Dividend0.000.000.000.000.000.00
Equity Dividend %2100.001050.000.000.000.000.00
Earnings Per Share-Unit Curr38.1134.17358.761597.44997.92-434.00
Earnings Per Share(Adj)-Unit Curr38.1134.17NANANANA
Book Value-Unit Curr174.51167.66768.112049.45449.62-1398.00